• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PMG Research boosts retention by donating vaccines to needy children on behalf of trial participants

PMG Research boosts retention by donating vaccines to needy children on behalf of trial participants

March 7, 2011
CenterWatch Staff

It’s common knowledge that many people enroll in clinical trials to be part of an effort that furthers medical innovation and ultimately helps others. And yet, after a trial wraps up, the vast majority of participants never learn the results, or whether their participation resulted in approval of a new drug.

Thomas Littlejohn—president and executive medical director of investigative-site group PMG Research—says this leaves a huge void that can make the trial participation experience less than satisfying and the participant less apt to return for a second trial.

Now PMG, based in Winston-Salem, N.C., has come up with a way to fill that void. For each volunteer who enrolls in a trial at one of PMG’s 11 sites, a pentavalent vaccine is

donated to a child in a third-world country. PMG launched the nonprofit Greater Gift Initiative (GGI) at the end of January, through which it has retroactively donated 6,700 vaccines, one for every person who enrolled in one of its trials in 2010. Now PMG, through GGI, is making donations quarterly.

To let participants know that enrolling in a trial resulted in a vaccine donation, GGI sends each trial enrollee a certificate proclaiming that he or she helped a child in need. This is key, said Littlejohn.

“It’s a tangible thing that says: I might not know what the results of this trial are but I know I did something good for someone else,” he said.

“It provides immediate positive reinforcement,” said Jennifer Byrne, PMG’s chief executive, who came up with the idea to donate vaccines after learning of Tom Shoes, which donates a pair of shoes to a person in need for every pair purchased.

Donating 6,700 vaccines on behalf of its 2010 trial participants cost PMG about $20,000, said Littlejohn, but it’s been well worth it, as the response has been phenomenal. After receiving their certificates, many of last year’s trial subjects have asked if they are eligible for other trials, said Byrne. And one principal investigator said he’d donate vaccines on behalf of each participant in his trials specifically.

Also, said Byrne, other investigative sites around the country have expressed interest in participating, and Byrne and Littlejohn are talking to sponsors about getting on board.

For now, GGI is working with Global Alliance for Vaccines and Immunization (GAVI) to distribute the pentavalent vaccine (Diphtheria, Tetanus, HiB, Pertussis, and Hepatitis B) in about 80 countries where it’s needed. GAVI is funded in large part by the Gates Foundation. Byrne said GGI may choose different groups to work with as the nonprofit grows.

Byrne said she hopes this type of effort could be the genesis of the image remake the industry needs. “There’s no reason our industry can’t give back in this way and at the same time turn around the public perception about clinical trials.”

-- Suz Redfearn

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing